Airways Clinical Research Centers - SAPS
Research Awards Nationwide Recipient (2013-2015)
About 20 percent of all people with asthma smoke. Smokers are consistently excluded from therapeutic trials for asthma. As a result current asthma treatment guidelines may not be appropriate for smokers. Indeed, there is good evidence that inhaled corticosteroids, the mainstay for treating persistent asthma, are less effective in smokers. The SAPS trial is designed to test the feasibility of a large scale clinical trial looking at the four main therapeutic options for asthmatic patients who still smoke and are not well controlled on standard asthma therapy. Smoking cessation remains the primary strategy for treating these patients but this study represents an important step toward improving care for that significant population of individuals with asthma for whom smoking cessation remains a struggle.